Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Want to cut your energy bills? Here’s how five experts are doing it 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
NEW YORK, March 29, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of INSYS Therapeutics, Inc. securities (NASDAQ:INSY) from March 3, 2015 through January 25, 2016, all dates inclusive (the “Class Period”) of the important April 4, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for INSYS Therapeutics investors under the federal securities laws.
To join the INSYS Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-834.html or call Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period issued materially false and misleading statements to investors and/or failed to disclose that: (1) INSYS Therapeutics was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain INSYS Therapeutics employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, INSYS Therapeutics’ financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-834.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
